NCT05987332 2026-02-17IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaIDEAYA BiosciencesPhase 2/3 Active not recruiting420 enrolled
NCT03947385 2026-01-27Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC FusionsIDEAYA BiosciencesPhase 1/2 Recruiting336 enrolled
NCT02223819 2023-12-06Crizotinib in High-Risk Uveal Melanoma Following Definitive TherapyColumbia UniversityPhase 2 Completed34 enrolled 9 charts